Tunisian adult's Hodgkin lymphoma Study Group

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Hodgkin lymphoma (HL) is a curable hematologic malignancy requiring standardized management.
• The Tunisian adult's Hodgkin lymphoma (HL) Study Group was established in 1999 to unify treatment approaches across national centers.
• Prior to the study group, management protocols varied, leading to suboptimal patient outcomes and high loss to follow-up.

Purpose of the Study:

• To improve the diagnosis, staging, treatment, and evaluation of adult Hodgkin lymphoma in Tunisia.
• To implement and refine prospective national treatment protocols (MDH series) based on evolving data.
• To enhance patient survival rates and reduce treatment-related mortality and disease progression.

Main Methods:

• Development and iterative improvement of four national treatment protocols (MDH99, MDH2002, MDH2008, MDH2015) for adult Hodgkin lymphoma.
• Standardization of diagnostic procedures, disease assessment, and therapeutic management across Tunisian hematology, oncology, and radiotherapy centers.
• Analysis of protocol outcomes to inform subsequent protocol revisions and literature-based updates.

Main Results:

• Significant reduction in patients lost to follow-up, from 30% to 3% (MDH2008).
• Improvement in complete and uncertain response rates from 75% to 92% (MDH2008).
• Overall survival increased from 57% to 90%, toxic death rate decreased from 13% (MDH2002) to 4.37% (MDH2008), and primary failure/relapse rates decreased.

Conclusions:

• The Tunisian national study group and standardized protocols have dramatically improved outcomes for adult Hodgkin lymphoma patients.
• The study demonstrates the effectiveness of a collaborative, protocol-driven approach in managing hematologic malignancies.
• Future objectives include further enhancing event-free survival to 80% with the integration of advanced imaging like positron emission tomography (PET).